Navigation Links
Immune Design Appoints Stephen R. Brady Chief Business Officer
Date:9/26/2013

SEATTLE and SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ -- Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the appointment of Stephen R. Brady as its Chief Business Officer.

(Logo: http://photos.prnewswire.com/prnh/20130926/SF87058LOGO)

Mr. Brady brings extensive experience to lead Immune Design's business functions, including strategic planning and corporate development activities. His appointment in this new position is a reflection of the Company's maturing immune-based therapeutic programs and productive platform technology.

"Steve is an experienced and accomplished executive with a successful track record of executing successful business development and corporate strategies," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. "He is a key addition to our expanded management team and will play an important role in advancing and expanding our strategic activities."

"Immune Design's combination of both novel antigen-specific and innate immunity approaches is an exciting potential advancement in the area of cancer immunotherapy," said Mr. Brady.  "I look forward to working with the team to move existing programs forward and further expand the reach of the company's platform technology in oncology, infectious disease and allergies."

Most recently, Mr. Brady served as Chief Business Officer for 3-V Biosciences, Inc., where he led business and operations activities, including finance, legal, corporate communications and strategic portfolio planning. Previously, he served as Vice President of Corporate Development for Proteolix, Inc., where he was primarily responsible for corporate development and legal affairs, including the sale of the Company to Onyx Pharmaceuticals for $851M in 2009. Prior to his tenure with Proteolix, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served primarily in business development and legal capacities.  Mr. Brady was also a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co, LLC., and an associate in the New York and San Francisco offices of Morrison & Foerster LLP.  Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from New York University School of Law.

The Immune Design Approach

Immune Design's immunotherapy approach is designed to both activate and deliver tumor antigens to dendritic cells in vivo to trigger specific, broad, and effective anti-tumor immune responses. The company's pipeline includes LV305 and G305 product candidates generated from two distinct technologies. Immune Design's proprietary lentiviral vector platform selectively targets dermal DCs in vivo to induce a powerful and durable pool of tumor specific cytotoxic T lymphocytes (CTLs). The company's synthetic TLR4 agonist, GLA, is a powerful inducer of innate immunity on its own and also triggers a potent and specific cellular and humoral anti-tumor immune response when it is combined with a tumor antigen. The LV305 and G305 product candidates will be individually tested in parallel in oncology indications and, upon demonstration of safety and immunogenicity, will then be tested in combination. These technologies may be applied in other allergy and infectious disease settings as well.

About Immune Design
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA.  Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. The company employs leading-edge technologies that target dendritic cells for more precise activation of the immune response. These include a novel lentiviral vector engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo and a TLR4 agonist that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces Th1 cytokines to enhance the immune response. For more information, visit www.immunedesign.com.


'/>"/>
SOURCE Immune Design
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
2. NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer
3. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
4. Researchers identify signals that direct the immune system to reject a transplanted organ
5. arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders
6. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
7. Penn researchers develop protein passport that help nanoparticles get past immune system
8. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
9. Small peptide ameliorates autoimmune skin blistering disease in mice
10. New Research Helps Explain Weakened Immune Response in Elderly
11. Autoimmune disease retraining white blood cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... established a new office dedicated to the North American healthcare market. , Aerocom ... to healthcare facilities. The company will provide new pneumatic tube systems or ...
(Date:2/3/2016)... -- Silk Therapeutics, Inc., today announced the closing of a $6 ... a total of $10.25 million in Series A funding based ... round was led by existing investor The Kraft Group of ... investors Lear Corporation and Highland Consumer Partners, as well as ... Richard Sackler , MD, with Summer Road, LLC; Erin ...
(Date:2/3/2016)... YORK. (PRWEB) , ... February 03, 2016 , ... ... of silicon (Si) and InGaAs chips and wafers, and InP epi wafers based ... ranging from silicon detectors–including photodiodes, photo transistors, and Avalanche photodiodes–to Si and InGaAs ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 This BCC Research ... market by reviewing the recent advances in high ... drive the field forward. Includes forecast through 2019. ... the challenges and opportunities that exist in the ... solution developers, as well as IT and bioinformatics ...
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/25/2016)... Jan. 25, 2016   Unisys Corporation (NYSE: UIS ... F. Kennedy (JFK) International Airport, New York City ... identify imposters attempting to enter the United States ... them. pilot testing of the system at Dulles ... terminals at JFK during January 2016. --> pilot testing ...
Breaking Biology News(10 mins):